U.S. Basic Materials Stock News

Liberty Energy overview Liberty Energy (LBRT) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but positive momentum over the past 3 months and the past year. See our latest analysis for Liberty Energy. Despite a recent 3.7% 1 day share price decline and a 4.6% 7 day share price pullback, Liberty Energy’s 30 day share price return of 6.2% and 90 day gain of 38.1% point to building momentum that aligns with its 1 year total shareholder...

In early March 2026, U.S. Bancorp completed multiple fixed-income offerings totaling more than US$90 million in senior unsecured, callable fixed-rate notes maturing between 2031 and 2046, including new 5.30% to 5.60% coupons across various tenors. These bond issues, alongside the previously announced BTIG acquisition and ongoing dividend and buyback activity, underscore U.S. Bancorp’s active use of the debt and equity markets to fund growth while fine-tuning its capital structure. We’ll now...

In late February 2026, Diamondback Energy reported fourth-quarter 2025 results showing revenue of US$3,376 million but a net loss of US$1,458 million driven largely by US$3,652 million of oil and natural gas property impairments, while also increasing its base cash dividend to US$1.05 per share and continuing share repurchases under its multi-year buyback program. The contrast between large non-cash impairments and continued commitments to higher dividends, production guidance, and...

American Tower (AMT) is back in focus after its Board declared a quarterly cash distribution of $1.79 per share, payable April 28 to shareholders of record on April 14, which has put its income profile under fresh scrutiny. See our latest analysis for American Tower. At a share price of $188.59, American Tower has seen a 10.11% 30 day share price return and a 7.89% year to date share price return. The 1 year total shareholder return of an 8.05% decline contrasts with a 9.11% total shareholder...

Adaptive Biotechnologies recently reported fourth-quarter 2025 results that exceeded analyst expectations, highlighting strong momentum in its Minimal Residual Disease business, while also filing a US$225.94 million shelf registration for up to 14,943,083 common shares tied to an employee stock ownership plan. At the same time, CEO Chad Robins and Chief Scientific Officer Harlan Robins executed sizable preplanned stock sales under Rule 10b5-1 trading plans, drawing attention to insider...

In February 2026, Viridian Therapeutics reported fourth-quarter and full-year 2025 results showing modest revenue of US$132,000 for the quarter and US$70.85 million for the year, alongside higher net losses, while also filing a US$16.33 million common stock shelf registration tied to an ESOP-related offering and presenting at a major healthcare conference. Beyond the financials, investor attention centers on Viridian’s progress toward potential FDA approval and commercial launch preparations...

Vail Resorts recently reported 739,000 skier visits, a 34.9% increase year on year, and is set to release its quarterly earnings, with analysts expecting earnings per share of $6.12 and a 4.1% revenue decline compared with the same quarter last year. Alongside this, the company has adjusted Epic Pass pricing by raising adult pass prices while introducing a 20% discount for skiers and riders under 30, aiming to address softer pass sales and make its resorts more accessible to younger...

Starbucks (SBUX) is in focus after announcing a new corporate office in Nashville, Tennessee, which will consolidate procurement teams to support supply chain efficiency and growth across the Southeastern U.S., drawing fresh market attention. See our latest analysis for Starbucks. The Nashville office announcement lands after a busy spell for Starbucks, with fresh analyst coverage, product tweaks and supply chain changes coinciding with a 90 day share price return of 18.68% and a 5 year total...

Recent share performance and what it might mean for investors BorgWarner (BWA) has drawn fresh attention after a mixed stretch in its share performance, with a 1.8% decline over the past day and a 10% drop over the past week. Those short term moves sit alongside a roughly flat month and a gain of about 24% over the past 3 months. This is prompting some investors to reassess how the auto technology supplier fits into their portfolio. See our latest analysis for BorgWarner. Set against a year...

Eli Lilly (LLY) is in focus after launching its Employer Connect platform for Zepbound, giving U.S. employers new ways to structure obesity drug coverage and work with GoodRx, Teladoc, and pharmacy partners. See our latest analysis for Eli Lilly. The Employer Connect launch sits against a mixed recent trading backdrop, with the latest share price at $990.33 after a 1 day share price return of 0.72%. Over the past 30 days the share price has declined 6.41%, while total shareholder return over...

What triggered the latest move in Distribution Solutions Group? Distribution Solutions Group (DSGR) is back in focus after its fourth quarter and full year 2025 earnings missed analyst expectations on both revenue and earnings, pressuring margins and sparking legal scrutiny following a sharp share price reaction. See our latest analysis for Distribution Solutions Group. The sharp post earnings drop has fed into a wider reset in expectations, with a 7 day share price return of 26.12% and a...

What just happened with Genworth Financial stock Genworth Financial (GNW) has drawn fresh attention after reporting fourth quarter and full year 2025 results, as well as completing a share buyback that retired more than 10 million shares. See our latest analysis for Genworth Financial. At a share price of US$8.43, Genworth’s short term share price returns, including a 1 month share price return of 6.64% decline and a year to date share price return of 6.02% decline, contrast with a 1 year...

In late February 2026, Vir Biotechnology announced a global collaboration with Astellas Pharma around its investigational prostate cancer therapy VIR-5500, alongside positive early Phase 1 data, a US$150,000,002 follow-on equity raise, new shelf registration and its 2025 earnings results. Together, the Astellas partnership economics, encouraging early VIR-5500 data and fresh equity capital appear to materially reshape Vir Biotechnology’s funding mix, oncology profile and long-term...

Why Immunovant is back on investors’ radar Immunovant (IMVT) has drawn fresh attention after completing enrollment in a potentially registrational IMVT-1402 trial for difficult rheumatoid arthritis, alongside a roughly US$550 million capital raise from institutional investors. See our latest analysis for Immunovant. At a share price of US$26.66, Immunovant has recently seen a 15.06% 90 day share price return and a 33.17% 1 year total shareholder return. This suggests momentum has built over...

If you are wondering whether NIKE's current share price reflects its true worth, you are not alone. The stock's long track record and strong brand often make investors ask what is actually a fair price. At the last close of US$57.01, NIKE's share price sits after a 7 day return of 8.3% decline, a 30 day return of 10.8% decline, a year to date return of 9.9% decline, and a 1 year return of 25.6% decline, alongside 3 year and 5 year returns of 48.6% and 56.2% declines respectively. Recent...

In the past quarter, West Pharmaceutical Services reported adjusted earnings per share of US$2.04 on revenue of US$805.00 million, raised its dividend, and authorized a share repurchase program alongside optimistic 2026 guidance tied to growing GLP-1 demand. This combination of earnings outperformance, confidence-backed capital returns, and GLP-1 exposure offers fresh context for assessing the company’s longer-term earnings power. We’ll now examine how West’s upbeat 2026 guidance, supported...

In early March 2026, Bath & Body Works reported fourth-quarter 2025 results showing lower sales of US$2,724 million and net income of US$403 million versus the prior year, and guided for 2026 net sales and earnings per share to decline, while also completing a share repurchase of 14,638,891 shares for US$382.85 million under its 2025 buyback plan. Management framed 2026 as a transition and investment year under its “Consumer First Formula,” refocusing on core fragrance and body care...

Why Slide Insurance Holdings is on investors’ radar Slide Insurance Holdings (SLDE) has drawn fresh attention after recent trading left the stock at US$18.48, with short term returns mixed and longer recent periods showing modest positive moves. For investors tracking insurers, Slide’s focus on coastal specialty homeowners and related property coverage, along with reinsurance and agency services, makes its latest price action a useful reference point when comparing peers and sector-specific...

Host Hotels & Resorts (HST) is back in focus after selling two resort properties for US$1.1b and outlining plans to recycle those proceeds into shareholder returns, acquisitions, and portfolio reinvestment. See our latest analysis for Host Hotels & Resorts. At a share price of US$19.23, Host Hotels & Resorts has seen short term share price pressure, with a 1 day return of 3.66% decline and a 7 day return of 1.84% decline. At the same time, a 90 day share price return of 12.46% and a 1 year...

Disc Medicine, Inc. reported full-year 2025 results showing a net loss of US$212.18 million, with basic loss per share from continuing operations of US$6.01, both higher than the prior year, and also filed a US$108.71 million common stock shelf registration related to its employee stock ownership plan. This combination of a larger annual loss and a sizeable ESOP-related shelf registration filing raises fresh questions about the company’s funding needs and capital structure priorities. With...

Recently, Smurfit Westrock raised recycled containerboard prices in Europe by €100 per metric ton, prompting expectations that peers such as International Paper could also benefit from a firmer pricing backdrop across the sector. This move underscores how pricing decisions by major European producers can ripple across global packaging markets, potentially influencing margin resilience and capacity discipline for International Paper. We’ll now examine how the prospect of wider containerboard...

Broadstone Net Lease (BNL) has been busy, adding two build-to-suit projects totaling about $62.1 million, closing a $350 million senior notes offering, and seeing its CFO increase his personal shareholding. See our latest analysis for Broadstone Net Lease. Those new build-to-suit commitments, the $350 million senior notes issuance and recent guidance sit against a 9.7% year to date share price return and a 20.8% 1 year total shareholder return, with shorter term momentum cooling slightly...

Autoliv, Inc. recently renewed its EUR 3,000 million guaranteed euro medium term note programme and appointed long‑time insider Monika Grama as Chief Financial Officer and Executive Vice President, Finance, effective April 1, 2026, succeeding outgoing CFO Fredrik Westin. The combination of refreshed funding flexibility through the EMTN programme and a new CFO with deep EMEA operational finance experience may influence how investors assess Autoliv’s financial policy and capital allocation...

Piper Sandler Companies recently expanded its healthcare investment banking franchise by appointing Jason Arnold as a managing director and naming Aamer Naseer global head of life sciences outsourcing and B2B medical technology, strengthening coverage across life science tools, diagnostics and medical devices. These hires deepen Piper Sandler’s sector expertise just as many investors are watching how specialized healthcare advisory capabilities could influence future fee opportunities and...